First published:13 December 2013Print ISBN:9783527333172 |Online ISBN:9783527675272 |DOI:10.1002/9783527675272 2014 Wiley‐VCH Verlag GmbH Co. KGaA About this book Edited by three pioneers in the field, each with longstanding experience in the biotech industry, and a skilled scientific writer, this is the first book to cover every step in the development and production of immunoglobulin Fc-fusion proteins as therapeutics for human disease: from choosing the right molecular design, to pre-clinical characterization of the purified product, through to batch optimization and quality control for large-scale cGMP production. The whole of the second part is devoted to case studies of Fc-fusion proteins that are now commercially successful products. In this section, the authors, several of whom were personally involved in clinical development of the products themselves, detail the product?s background and give insight into issues that were faced and how these issues were overcome during clinical development. This section also includes a chapter on promising new developments for the future. An invaluable resource for professionals already working on Fc-fusion proteins and an excellent and thorough introduction for physicians, researchers, and students entering the field. Reviews

\"In conclusion, this is an excellent book that combines the theory and practice of the Fc-fusion protein and peptides. It is a valuable book for those readers working in the development of biologics but also for the general readers interested in how the most advanced and sophisticated drugs are developed.”  (ChemMedChem, 1 February 2015)

\"I found Therapeutic Fc-Fusion Proteins to be thorough, timely and well written. . . . This book would be of interest to a wide biopharmaceutical audience, from scientists in discovery through development and analytics, as well as to manufacturing personnel and clinicians. I recommend it both as an informative, comprehensive review of the field and a valuable reference text.\" (mAbs, July/August 2014) Author Bios

Steven M. Chamow, PhD is currently the principal at Chamow & Associates, Inc., a biopharmaceuticalconsulting firm. He has developed protein therapeutics for 26 years and contributed to the development of three marketed products (Avastin, Natrecor, Vectibix). He began his career in process development at Genentech, Inc. and has served in management and executive roles at several other biotechnology companies. He is author or co-author of more than 45 scientific publications and patents and co-editor of a 1999 book entitled Antibody Fusion Proteins. Educated at the University of California and trained at the National Institutes of Health, he lives in San Mateo, CA with his wife.

Thomas Ryll, PhD currently serves as Senior Director of Cell Culture Development at Biogen Idec in Cambridge, MA. He has contributed to the development of several marketed products, including Rituxan, Raptiva, Vectibix, Eloctate and Alprolix. He began his career at Genentech, Inc. as scientist in process development. Since then, he served in various scientific and management roles with increasing responsibilities at Abgenix, Inc., Tanox Inc., and Biogen Idec, Inc. Educated at the Technical University of Braunschweig in Germany, he is author or co-author of more than 35 scientific publications and patents. He lives in Lexington, MA with his family.

Henry B. Lowman, PhD currently serves as Chief Scientific Officer at CytomX Therapeutics, Inc. Dr. Lowman served a 20-year tenure at Genentech, Inc., where he focused on protein and antibody therapeutics. His career interests include structure-based protein design, structure-function analysis, and molecular diversity techniques. Dr. Lowman is an author on more than 60 scientific publications, inventor on more than 60 issued patents, and an editorial board member for the antibody journal mAbs. Dr. Lowman earned his B.A. in chemistry at Johns Hopkins University and PhD in chemistry at Purdue University.

Deborah Farson is the principal at FarsonInk, a scientific, medical writing firm. Deborah Farsonworked as a cell biologist at Cell Genesys, Inc. for 19 years. As a Senior Director of Research and Development, Deborah Farson was responsible for the development and characterization of cell lines for use as immunotherapy products. In addition, her department developed cell lines for use in assay development and for production of recombinant proteins and antibodies. She is an author or co-author on 16 peer-reviewed journal articles and 4 issued patents. Deborah Farson currently resides in Santa Fe, NM.

Select / Deselect allExport Citation(s)Export CitationFormatPlain TextRIS (ProCite, Reference Manager)EndNoteBibTexMedlarsRefWorksType of importCitation file or direct importIndirect import or copy/pastePlease select some articles/chapters to export citations.For help, please view the citation helpCitation HelpCancelExportCitation HelpCloseIntroduction: Antibody Structure and Function (Pages: 1-44) Arvind Rajpal Pavel Strop Yik Andy Yeung Javier Chaparro‐Riggers Jaume PonsFc‐Fusion Protein Expression Technology (Pages: 45-66) Jody D. Berry Catherine Yang Janean Fisher Ella Mendoza Shanique Young Dwayne StupackCell Culture‐Based Production (Pages: 67-96) Yao‐Ming Huang Rashmi Kshirsagar Barbara Woppmann Thomas RyllQuality by Design Applied to a Fc‐Fusion Protein: A Case Study (Pages: 155-189) Alex Eon‐Duval Ralf Gleixner Pascal Valax Miroslav Soos Benjamin Neunstoecklin Massimo Morbidelli Hervé Broly

Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account.

Can\'t sign in? Forgot your username?

Enter your email address below and we will send you your username

If the address matches an existing account you will receive an email with instructions to retrieve your username

>>> 更多资讯详情请访问蚂蚁淘商城